Clear market notes built around the JSE, the rand, and what matters locally.

2026-09-29 09:35 • The Motley Fool Positive Axe Cap view: Selective

Teva Pharmaceutical has surged 110% in the last year, hitting a 52-week high of $40.79 per share, driven by its pivot from generic to branded drugs. The company's innovative portfolio of three branded products is projected to generate $3.7 billion in 2026 revenue, while net debt has decreased from $18.4 billion (end of 2022) to $12.9 billion, earning a credit rating upgrade to investment-grade status. With peak annual sales of $10 billion anticipated from its late-stage pipeline and earnings expected to grow 40.7% between 2026-2027, analysts view the stock as undervalued at 12.9x forward earnings.

Axe note: Teva Pharmaceutical’s pivot from generic to branded drugs has sparked a major share rebound, but South African investors should weigh currency risks.

2026-09-29 09:30 • The Motley Fool Positive Axe Cap view: Selective

Bitcoin and Ethereum dominate Wall Street's cryptocurrency investments, with 12 and 6 of the top 20 spot crypto ETFs respectively. Bitcoin is praised as a unique portfolio diversifier with both risk-on and risk-off properties, while Ethereum leads in DeFi applications like asset tokenization and stablecoins. Other cryptocurrencies like Solana, XRP, and Zcash have spot ETFs but attract significantly less institutional capital.

Axe note: Bitcoin and Ethereum lead institutional crypto bets, with some interesting implications for the rand and SA investors.

2026-09-29 09:21 • The Motley Fool Positive Axe Cap view: Selective

Bristol Myers Squibb trades at a low P/E ratio of 9 despite a 42.5% stock surge over the past year, reflecting investor uncertainty about its ability to offset major patent expirations. However, the company's strong growth portfolio (up 15%) and new drug launches suggest successful patent cliff mitigation, potentially offering upside if 2027-2028 results exceed expectations.

Axe note: Patent expirations weigh on Bristol Myers Squibb’s valuation, but growth prospects suggest upside.